Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
about
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesDiscovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indicationsFragment Screening of Soluble Epoxide Hydrolase for Lead Generation-Structure-Based Hit Evaluation and Chemistry ExplorationSoluble epoxide hydrolase inhibitors and heart failureSoluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitorPharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammationThe 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic painEpoxides and soluble epoxide hydrolase in cardiovascular physiologyPharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsDevelopment of a high-throughput screen for soluble epoxide hydrolase inhibitionThe 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolaseSolid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosisHigh-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesAntitumor agents. 289. Design, synthesis, and anti-breast cancer activity in vivo of 4-amino-2H-benzo[h]chromen-2-one and 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogues with improved water solubility.1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.Structure-activity relationships of cycloalkylamide derivatives as inhibitors of the soluble epoxide hydrolase.Orally bioavailable potent soluble epoxide hydrolase inhibitors.Design, synthesis and biological evaluation of 4-benzamidobenzoic Acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitorsSoluble epoxide hydrolase inhibitors: a patent review.Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.Total synthesis of a glycoglycerolipid from Meiothermus taiwanensis through a one-pot glycosylation reaction and exploration of its immunological properties.14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.Peptidyl-urea based inhibitors of soluble epoxide hydrolases.Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications.1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolaseEpoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis.Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.
P2860
Q24597172-F854DE9F-F2C9-4F3F-9022-48429A583338Q24616753-7F9305F9-DD55-495F-80DB-DDD9C5F74F86Q27703977-48A1079E-CEB4-4E06-A267-B41201FFE005Q28383423-EC71944D-5573-4418-94DE-0AEBDC3B4FBCQ28387686-C9B46D73-4226-4229-9365-EE627BFA932DQ28389323-1BF4E7AD-06A8-4619-A681-1A0762BD9FFEQ28392416-E7BAAEF5-DC89-4F3E-96DA-DCBEBD2D4330Q28396313-520BD179-D25A-4D45-95CA-FED3B7BB30B2Q28396888-8BC8967F-ADC6-4788-A0BB-E7325CD6323AQ30816822-1781EB35-5953-43DF-BCD7-539369BE88A1Q33247246-94612117-2F96-4052-9019-530609DD1EAAQ33256176-9E2B1C41-DA27-4C1B-B154-2F96FFE862E2Q33260049-6E61331D-1260-49D5-ABC8-07E5F297D28FQ33503956-B5B83CA2-416D-4A97-BEDC-EBEAEC7A0987Q33605509-1D9110A8-4821-4808-921B-F9156F049E34Q33744236-96AB5D01-C0B2-42A5-9488-DA2DF512BA43Q34231319-1E843D04-FE25-4D1C-99A5-071E2DC64350Q34241120-80DF0F0F-CC8E-49D7-AD76-6C0295B334FAQ34329204-A7695409-FFE4-43DD-A936-78E7328CB80AQ35850997-8C5A980C-F552-4B85-8417-B3B9C9D50D82Q36302996-D72F9351-0D1B-40F8-BCD0-3AA68F7EC56BQ36453292-3F7BDB10-635A-4FB0-A55B-A21153E36881Q36999511-155E640E-091B-4473-8C00-7121E6DFB9D0Q37687169-857D944B-B519-41B6-BA1A-21757B4D23A0Q37739429-4499D6C6-8CFF-486D-82DA-5FE80FDC0E31Q38184587-2F3E51D2-78FF-4800-92F4-A3B778CFC74AQ38785907-38613BC2-CB88-42D6-8ECC-69232AE85E11Q39095616-8137B4FE-9E0B-4465-BC2B-869E6CE80B37Q41202514-4C9926F6-E493-46C9-B8DD-39A487D6794DQ41486228-E61CE1B3-EF1C-4717-BCDC-348BA2BC09C9Q41824971-6C102AC2-8A2B-4BDF-96A5-8020CF8DE5A2Q41833401-90365594-9173-4158-AA45-65F36586E33DQ41839063-DF9F1CDD-14FF-4F87-96E6-94FB7B4BBBF9Q41855025-49707320-F372-40CD-BC1B-61E9C49BB991Q42032140-A6BCA2D0-2804-48B0-9DE8-9AF74381C58DQ42070301-C970B851-833B-410A-8F5C-C3AA4E55BEA8Q42255159-CBE4FA00-CE66-4E78-A3F3-C40EE1BD324BQ42322454-912D9B5F-076F-4129-8B2F-1F825FA37135Q42531772-DC3C5EC9-E30C-434A-A7BE-A0D668C097E3Q42547462-9A714A59-0B1D-4305-A925-D97FE6338B58
P2860
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Optimization of amide-based in ...... ith improved water solubility.
@en
type
label
Optimization of amide-based in ...... ith improved water solubility.
@en
prefLabel
Optimization of amide-based in ...... ith improved water solubility.
@en
P2093
P2860
P356
P1476
Optimization of amide-based in ...... ith improved water solubility.
@en
P2093
Bruce D Hammock
Christophe Morisseau
Fenton R Heirtzler
Hsing-Ju Tsai
In-Hae Kim
P2860
P304
P356
10.1021/JM0500929
P407
P50
P577
2005-05-01T00:00:00Z